Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Schering-Plough, Incyte Report Positive Mid-Stage Data For CCR5 Antagonists

Jul 24 2007

• By Pamela Taulbee

Related Content

Pfizer’s Maraviroc Deemed “Approvable” By FDA

Jun 21 2007

Pfizer’s Maraviroc Unanimously Recommended For Accelerated Approval

Apr 25 2007

Incyte’s CCR5 Antagonist Has “Meaningful Advantages” Over Pfizer’s Maraviroc, Firm Says

May 03 2007

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window